Vaccinia virus with the E3L gene deleted was able to replicate in RK-13 but not HeLa cells. This host range phenotype could be complemented by an E3L gene expressed transiently from a plasmid. Analysis of mutants of E3L indicates that the ability to complement deletion of E3L correlates with the ability of mutated proteins to bind double-stranded RNA but not with their ability to migrate to the nucleus.
Vaccinia virus with the E3L gene deleted was able to replicate in RK-13 but not HeLa cells. This host range phenotype could be complemented by an E3L gene expressed transiently from a plasmid. Analysis of mutants of E3L indicates that the ability to complement deletion of E3L correlates with the ability of mutated proteins to bind double-stranded RNA but not with their ability to migrate to the nucleus.
Vaccinia virus (VV) is resistant to the antiviral effects of interferon (IFN) in most cell types tested (21) and can rescue normally IFN-sensitive viruses, such as vesicular stomatitis virus (19) and encephalomyocarditis virus (20) , from the antiviral effects of IFN. The VV E3L (2) and K3L (4) genes are necessary for IFN resistance of VV replication in mouse L929 cells. Both genes can inhibit the IFN-induced, double-stranded RNA (dsRNA)-dependent protein kinase (PKR) (6, 9, 10) . The E3L gene encodes the dsRNA-binding proteins p20 and p25 (8, 18, 22) , which are thought to function by binding dsRNA and inhibiting both PKR and the IFN-induced, dsRNA-dependent enzyme 2Ј,5Ј-oligoadenylate synthetase (2) . VV with E3L deleted also has a host range phenotype in that it replicates normally in CEF (3) or RK-13 cells but cannot replicate in Vero (3) or HeLa cells. Vaccinia virus with K3L deleted replicates normally in Vero cells (4) . Results of single-step growth experiments with RK-13 and HeLa cells for wild-type (wt) VV and VV with E3L deleted (vP1080) are shown in Fig. 1 . Confluent monolayers of RK-13 or HeLa cells were treated with the concentrations of rabbit or human IFN-␣ (Lee Biomolecular), respectively, indicated in Fig. 1 . After 24 h, the cells were infected with wt VV or VV vP1080 at a multiplicity of infection of 5 PFU per cell. After 24 h, monolayers were harvested, virus was released by repeated freezing and thawing, and released virus was quantified by a plaque assay on monolayers of RK-13 cells. In the absence of IFN treatment, VV vP1080 replicated as efficiently as wt VV in RK-13 cells. While replication of wt In order to analyze the mechanism by which E3L promotes replication of VV in HeLa cells, we have developed a transient-transfection assay for rescue of VV vP1080 replication in HeLa cells. HeLa cells were transfected with E3L constructs (indicated in Fig. 2 and 3 ) derived from the eukaryotic expression vector pMT-2VaϪ (pMT) (7, 13) . Transcription of the E3L gene in these constructs is driven by an adenovirus major late promoter. At 48 h posttransfection, cells were infected with either wt VV or VV vP1080 at a multiplicity of infection of 5 PFU per cell. Synthesis of proteins was analyzed after the cells were labelled with [ Fig. 3 ). Expression of E3L from a plasmid had no effect on protein synthesis in cells infected with wt VV (Fig. 2, lanes 5 and 6) . Similar results were seen when replication of VV vP1080 was analyzed. Transfection with pMT-E3L led to an approximately 1,000-fold increase in replication of VV vP1080 (Fig. 4) , to a level within 25% of the wt VV replication level.
We have previously characterized a number of E3L mutants in terms of the ability of their encoded proteins to bind to dsRNA and inhibit PKR in vitro (7) . Deletion of 26 C-terminal amino acids from the E3L-encoded proteins destroyed the ability of the proteins to bind to dsRNA and inhibit PKR (7). Expression of this gene (⌬26C, previously called E3L/3-5 [7] ) from pMT could not detectably rescue protein synthesis in VV vP1080-infected cells (Fig. 3, lane 6 ) and did not rescue replication of VV vP1080 to a greater extent than did the parental plasmid, pMT (Fig. 4) . Deletion of 83 N-terminal amino acids from the E3L-encoded proteins did not affect binding to dsRNA or inhibition of PKR (7) . Expression of this gene (⌬83N, previously called E3L/AatII [7] ) from pMT rescued VV vP1080 protein synthesis (Fig. 3, lane 7) and replication of VV vP1080 (Fig. 3) nearly as efficiently as wt E3L. Mutation of glycine 164 or alanine 174 to valine (G164V and A174V, re- 1, 3, 4, 7, 8, and 9) . At 48 h posttransfection, cells were infected with either wt VV (lanes 3 to 6) or VV vP1080 (lanes 8 to 11), or were mock infected (M) (lanes 1, 2, and 7). spectively) destroyed the ability of the E3L-encoded proteins to bind dsRNA and inhibit PKR (7). Neither mutation allowed rescue of VV vP1080 protein synthesis (Fig. 3, lanes 8 and 12 , respectively) or rescue of VV vP1080 replication (Fig. 4) . Mutation of glycine 164 to alanine (G164A) or alanine 174 to glycine (A174G) did not appreciably affect dsRNA binding or PKR inhibition (7). Both G164A and A174G rescued VV vP1080 protein synthesis (Fig. 3, lanes 9 and 11) and VV vP1080 replication (Fig. 4) . Finally, deletion of seven C-terminal amino acids (⌬7C, previously called E3L/2-2 [7] ) reduced the affinity of the encoded proteins for dsRNA nearly 100-fold in comparison with wt E3L (7). Expression of this gene from pMT rescued VV vP1080 protein synthesis poorly (Fig. 3, lane  14) and rescued replication of VV vP1080 10-fold less efficiently than wt E3L (Fig. 4) . For each of the mutants analyzed, E3L-encoded proteins were expressed in HeLa cells at comparable levels (data not shown), suggesting that differences in efficiency of rescue were not due to differences in levels of expression. The E3L-encoded proteins are present both in the nucleus and in the cytoplasm of infected and transfected cells (22) (Fig.  5A) . In order to determine if any of the mutations tested led to proteins with altered localization in the cells, we visualized several of these proteins by indirect immunofluorescence at 24 h posttransfection, using monospecific anti-E3L serum (18) . Deletion of 83 N-terminal amino acids prevented localization of the E3L-encoded proteins to the nucleus (Fig. 5B) . Since ⌬83N bound to dsRNA as efficiently as wt E3L and rescued virus replication as efficiently as wt E3L, it appears that nuclear localization of E3L-encoded proteins is not necessary for replication of VV in HeLa cells. All results for dsRNA binding, nuclear localization, and rescue of VV vP1080 protein synthesis and replication are summarized in Table 1 . The results suggest that the ability of mutants of E3L to rescue VV vP1080 protein synthesis and replication correlates with their ability to bind dsRNA. All mutations that destroyed the ability of the E3L-encoded proteins to bind dsRNA destroyed the ability to rescue VV vP1080 protein synthesis and replication. Mutant ⌬7C, which bound dsRNA with reduced affinity, rescued VV vP1080 protein synthesis and replication poorly. In addition, replication of VV vP1080 could be rescued by several related (group C rotavirus NSP3 protein [14] and human TAR/Rev response elementbinding protein [15] ) and unrelated (reovirus 3 protein [2, 12] ) dsRNA-binding proteins. In the case of 3, which has no sequence homology to E3L, the ability of mutants to bind to dsRNA correlated with their ability to rescue protein synthesis in VV vP1080-infected HeLa cells (2) . For the group C rotavirus NSP3 protein, a 69-amino-acid peptide containing the dsRNA-binding motif is sufficient to rescue replication of VV vP1080 in HeLa cells (17) . All of these results suggest that the sole function of E3L in promoting replication of VV in HeLa cells is binding dsRNA.
The ability to localize to the nucleus did not appear necessary for rescue of VV vP1080 replication, since ⌬83N, which did not localize to the nucleus, rescued replication of VV vP1080 nearly as efficiently as wt E3L did. It is somewhat surprising that ⌬83N rescued replication of VV vP1080 nearly as well as wt E3L. The entire E3L gene is well conserved between ectromelia virus (5), VV (11), and variola virus (16) , suggesting that the entire protein is required for some function in these viruses. However, the N-terminal 45% of the protein appears dispensable for replication in HeLa cells and dispens- This work was supported in part by Public Health Service grant CA-48654 from the National Cancer Institute.
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